1. Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer. (23rd October 2020) Authors: Madan, Ravi A.; Karzai, Fatima H.; Al Harthy, Munjid; Petrylak, Daniel P.; Kim, Joseph W.; Arlen, Philip M.; Rosner, Inger; Theoret, Marc R.; Cordes, Lisa; Bilusic, Marijo; Peer, Cody J.; Dawson, Nancy A.; Couvillon, Anna; Hankin, Amy; Williams, Moniquea; Chun, Guin; Owens, Helen; Marte, Jennifer... Journal: BJU international Issue: Volume 127:Number 4(2021) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. (25th March 2021) Authors: Mathieu, Luckson; Shah, Sujay; Pai‐Scherf, Lee; Larkins, Erin; Vallejo, Jonathon; Li, Xiaoxue; Rodriguez, Lisa; Mishra‐Kalyani, Pallavi; Goldberg, Kirsten B.; Kluetz, Paul G.; Theoret, Marc R.; Beaver, Julia A.; Pazdur, Richard; Singh, Harpreet Journal: Oncologist Issue: Volume 26:Number 5(2021) Page Start: 433 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. (10th June 2021) Authors: Saung, May Tun; Pelosof, Lorraine; Casak, Sandra; Donoghue, Martha; Lemery, Steven; Yuan, Mengdie; Rodriguez, Lisa; Schotland, Peter; Chuk, Meredith; Davis, Gina; Goldberg, Kirsten B.; Theoret, Marc R.; Pazdur, Richard; Fashoyin-Aje, Lola Journal: Oncologist Issue: Volume 26:Number 9(2021) Page Start: 797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. (10th June 2021) Authors: Saung, May Tun; Pelosof, Lorraine; Casak, Sandra; Donoghue, Martha; Lemery, Steven; Yuan, Mengdie; Rodriguez, Lisa; Schotland, Peter; Chuk, Meredith; Davis, Gina; Goldberg, Kirsten B.; Theoret, Marc R.; Pazdur, Richard; Fashoyin‐Aje, Lola Journal: Oncologist Issue: Volume 26:Number 9(2021) Page Start: 797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Issue 30 (20th October 2022) Authors: Fourie Zirkelbach, Jeanne; Shah, Mirat; Vallejo, Jonathon; Cheng, Joyce; Ayyoub, Amal; Liu, Jiang; Hudson, Rachel; Sridhara, Rajeshwari; Ison, Gwynn; Amiri-Kordestani, Laleh; Tang, Shenghui; Gwise, Thomas; Rahman, Atiqur; Pazdur, Richard; Theoret, Marc R. Journal: Journal of clinical oncology Issue: Volume 40:Issue 30(2022) Page Start: 3489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer. (19th February 2016) Authors: Madan, Ravi A.; Karzai, Fatima H.; Ning, Yang‐Min; Adesunloye, Bamidele A.; Huang, Xuan; Harold, Nancy; Couvillon, Anna; Chun, Guinevere; Cordes, Lisa; Sissung, Tristan; Beedie, Shaunna L.; Dawson, Nancy A.; Theoret, Marc R.; McLeod, David G.; Rosner, Inger; Trepel, Jane B.; Lee, Min‐Jung; Tomita... Journal: BJU international Issue: Volume 118:Number 4(2016:Aug.) Page Start: 590 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. (27th July 2021) Authors: Chang, Elaine; Pelosof, Lorraine; Lemery, Steven; Gong, Yutao; Goldberg, Kirsten B.; Farrell, Ann T.; Keegan, Patricia; Veeraraghavan, Janaki; Wei, Guo; Blumenthal, Gideon M.; Amiri-Kordestani, Laleh; Singh, Harpreet; Fashoyin-Aje, Lola; Gormley, Nicole; Kluetz, Paul G.; Pazdur, Richard; Beaver, ... Journal: Oncologist Issue: Volume 26:Number 10(2021) Page Start: e1786 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. (27th July 2021) Authors: Chang, Elaine; Pelosof, Lorraine; Lemery, Steven; Gong, Yutao; Goldberg, Kirsten B.; Farrell, Ann T.; Keegan, Patricia; Veeraraghavan, Janaki; Wei, Guo; Blumenthal, Gideon M.; Amiri‐Kordestani, Laleh; Singh, Harpreet; Fashoyin‐Aje, Lola; Gormley, Nicole; Kluetz, Paul G.; Pazdur, Richard; Beaver, ... Journal: Oncologist Issue: Volume 26:Number 10(2021) Page Start: e1786 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Using a Benefit–Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma. Issue 1 (21st May 2019) Authors: Raju, G. K.; Gurumurthi, Karthik; Domike, Reuben; Theoret, Marc R.; Pazdur, Richard; Woodcock, Janet Journal: Clinical pharmacology & therapeutics Issue: Volume 106:Issue 1(2019) Page Start: 123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗